Pure Global

An Exploratory Clinical Study of Adebelimumab in Combination With Famitinib and Chemotherapy in Patients With NSCLC - Trial NCT06332300

Access comprehensive clinical trial information for NCT06332300 through Pure Global AI's free database. This Phase 2 trial is sponsored by Jiangsu Province Nanjing Brain Hospital and is currently Recruiting. The study focuses on NSCLC. Target enrollment is 28 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06332300
Phase 2
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06332300
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
An Exploratory Clinical Study of Adebelimumab in Combination With Famitinib and Chemotherapy in Patients With NSCLC
An Exploratory Clinical Study of Adebelimumab in Combination With Famitinib and Lateral Ventricular Chemotherapy in Patients With Non-squamous NSCLC With Soft Meningeal Metastases Who Have Failed EGFR-TKI Therapy

Study Focus

NSCLC

Adebelimumab+Famitinib + FOLFIRI+Ariely

Interventional

drug

Sponsor & Location

Jiangsu Province Nanjing Brain Hospital

Nanjing, China

Timeline & Enrollment

Phase 2

Feb 01, 2024

Feb 01, 2026

28 participants

Primary Outcome

ORR

Summary

This study was a single-arm design to explore the efficacy and safety of Adebelimumab in
 combination with famitinib and lateral ventricular chemotherapy in patients with floppy
 meningeal metastases from non-squamous NSCLC who have failed EGFR-TKI therapy, and included
 patients with pathologically confirmed non-squamous non-small cell lung cancer.

Data Source

ClinicalTrials.gov

NCT06332300

Non-Device Trial